Navigation Links
ConjuChem to evaluate strategic alternatives
Date:1/19/2010

MONTRÉAL, Jan. 19 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies, Inc. (TSX: CJB) announced today that it has established a Special Committee of independent Board members to explore and evaluate all strategic alternatives including, but not limited to, a sale of the Company or the sale of all or a substantial part of its assets. The Committee will be working with management and external consultants to expeditiously make recommendations as to the optimal path forward for ConjuChem and all its stakeholders. The Committee will be chaired by Jacques Lapointe, Chairman of the Board, and include Steve Perrone and William Heiden.

At this time, ConjuChem has not made a decision to pursue any specific strategic transaction or other strategic alternative but there is an expectation that this process will result in a transaction or other strategic alternative being implemented. ConjuChem does not intend to comment further on this process unless and until its Board of Directors has approved a specific transaction or other strategic alternative.

About ConjuChem

ConjuChem, developer of next generation medicines from therapeutic peptides, is creating long-acting compounds based on bioconjugation platform technologies. When applied to peptides, the Company's systemic PC-DAC(TM) Technologies enable the creation of new drugs with significantly enhanced therapeutic properties as compared to the original peptide.

The Company has two major development programs: PC-DAC(TM):Exendin-4, a GLP-1 agonist in Phase II for the treatment of Type II diabetes and PC-Insulin, a long-acting basal insulin in preclinical testing.

Detailed descriptions of the Company and its technologies can be viewed on the Company's website www.conjuchem.com.

Forward-Looking Statements

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause ConjuChem's actual results, performance or achievements to be materially different from those expressed or implied by any of the Company's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

SOURCE ConjuChem Biotechnologies Inc.


'/>"/>
SOURCE ConjuChem Biotechnologies Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ConjuChem Provides Development Update
2. ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4
3. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
4. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
5. K-State Research Leading to Software to Help Nations Cattle Producers Identify Biosecurity Risks, Evaluate Impact of Cow-Calf Diseases Online
6. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
7. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
10. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
11. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... PA (PRWEB) , ... February 09, 2016 , ... Tunnell ... Europe. Based in Paris, he will focus on acquiring new accounts and work ... met. , “Fred brings to our European clients more than 15 ...
(Date:2/9/2016)... , Feb. 9, 2016  DNAtrix, a ... for cancer, announced that its lead product, ... Commission as an orphan medicinal product for ... form of glioma, strikes approximately 25,000 people ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> ...
(Date:2/9/2016)... , Feb. 9, 2016 BERG, a ... biological research approach, has announced the appointment of ... and Chief Operating Officer. Haddock brings to BERG ... including 12 years in senior financial functions at ... in business organizational management. Niven ...
(Date:2/8/2016)... , Feb. 8, 2016  CytRx Corporation ... development company specializing in oncology, today announced that ... security agreement with Hercules Technology Growth Capital, Inc. ... $40 million in financing. --> ... first $25 million of financing under the loan ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce the attainment of record-setting corporate ... of the company,s laser focus on (and growing international ... comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... growth achievements in 2015 include: , Record ...
(Date:1/13/2016)... New York , January 13, 2016 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2023. According to the ... in 2014 and is anticipated to reach US$1,625.8 mn ... 2015 to 2023. In terms of volume, the biometric ...
Breaking Biology News(10 mins):